Veracyte (VCYT)
(Delayed Data from NSDQ)
$22.88 USD
-0.52 (-2.22%)
Updated May 17, 2024 04:00 PM ET
After-Market: $22.73 -0.15 (-0.66%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
VCYT 22.88 -0.52(-2.22%)
Will VCYT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VCYT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VCYT
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade
Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings
VCYT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View
Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
Other News for VCYT
July 19th Options Now Available For Veracyte (VCYT)
Veracyte to Participate in Upcoming Investor Conferences
Veracyte’s Robust Performance and Growth Potential Reinforce Buy Rating
Veracyte’s Strong Q1 Performance and Upbeat Outlook Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT) and Argenx Se (ARGX)